Skip to main content

Allied health – 3007. The biomarker of sublingual immune therapy


Allergic rhinitis (AR) is recognized as a major health problem worldwide. Allergen-specific immunotherapy (SIT) is the only available treatment that can alter the natural course of allergic disease. Recent findings in experimental models of allergic rhinitis suggest that complement 3a and 5a regulate the development of maladaptive Th2 and Th17 immunity. We investigated the changes of C3a, C5a, IL-17a in the serum of patients treated by Sublingual immune therapy (SLIT).


Symptoms were recorded in the allergy diary. The total symptom medication scores were calculated based on each symptoms and medication. We measured the C3a, C5a, IL-17a levels in serum of the 20 identical subjects by ELISA during 5 years.


C3a and IL-17a showed significant decrease year by year during 5 years (p < 0.01).


C3a and IL-17a can be objective biomarker for following up the patients of SLIT.

Author information



Corresponding author

Correspondence to Masafumi Sakashita.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Sakashita, M., Imoto, Y., Osawa, Y. et al. Allied health – 3007. The biomarker of sublingual immune therapy. World Allergy Organ J 6, P183 (2013).

Download citation

  • Published:

  • Issue Date:

  • DOI:


  • Health Problem
  • Experimental Model
  • Rhinitis
  • Allergic Rhinitis
  • Allergic Rhinitis